Henry Hagopian's most recent trade in Annovis Bio Inc was a trade of 820 Common Stock done at an average price of $6.1 . Disclosure was reported to the exchange on Nov. 20, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Annovis Bio Inc | Henry Hagopian | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 6.10 per share. | 20 Nov 2023 | 820 | 1,820 (0%) | 0% | 6.1 | 5,002 | Common Stock |
| Annovis Bio Inc | Henry Hagopian | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 12.61 per share. | 07 Apr 2023 | 1,000 | 1,000 (0%) | 0% | 12.6 | 12,610 | Common Stock |
| Annovis Bio Inc | Henry Hagopian | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2023 | 7,672 | 7,672 | - | - | Stock Option (right to buy) | |
| Annovis Bio Inc | Henry Hagopian | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Aug 2022 | 120,000 | 120,000 | - | - | Stock Option (right to buy) |